title: The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
abstract: BACKGROUND
  Pemphigus vulgaris is an autoimmune blistering disease for which the mainstay of treatment is systemic corticosteroids and immunosuppressants. This therapy had reduced the mortality of pemphigus; however, it is associated with significant morbidity.
  
  
  OBJECTIVE
  The objective of this study was to assess the group's experience with plasmapheresis in the treatment of pemphigus vulgaris and report on its utility.
  
  
  METHODS
  Seven patients with severe or resistant pemphigus vulgaris underwent a series of 5 plasma exchanges over an average of 8 days. Immunosuppressive drugs were administered immediately after plasmapheresis to prevent the "rebound" flare of disease that can occur after plasmapheresis.
  
  
  RESULTS
  Remission was induced in 4 patients, partial remission was induced in 2 patients, and 1 patient continues to have active disease.
  
  
  CONCLUSIONS
  This study suggests that plasmapheresis is a useful intervention in patients with pemphigus vulgaris who are not responding to standard therapy or who require unacceptably high doses of steroids or immunosuppressants.
authors: Upstate Medical University, Syracuse, NY, USA.
authors: M S
authors: MS
authors: Turner
authors: D
authors: D
authors: Sutton
authors: D N
authors: DN
authors: Sauder
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000175:diagnosis / Q000628:therapy*; D010956:Plasmapheresis / Q000379:methods*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents